ProfileGDS5678 / 1428746_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 87% 86% 87% 89% 88% 87% 85% 87% 87% 87% 88% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.825288
GSM967853U87-EV human glioblastoma xenograft - Control 26.6486986
GSM967854U87-EV human glioblastoma xenograft - Control 36.6955587
GSM967855U87-EV human glioblastoma xenograft - Control 46.6281586
GSM967856U87-EV human glioblastoma xenograft - Control 56.804887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7019189
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6975588
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.585787
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3184885
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6983687
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6141187
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7936987
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7886988
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7278687